FY2028 EPS Estimates for Invivyd Decreased by HC Wainwright

Invivyd, Inc. (NASDAQ:IVVD) – Investment analysts at HC Wainwright dropped their FY2028 EPS estimates for shares of Invivyd in a report released on Monday, August 18th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of $0.13 for the year, down from their previous estimate of $0.18. HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Invivyd’s current full-year earnings is ($1.64) per share. HC Wainwright also issued estimates for Invivyd’s FY2029 earnings at $0.22 EPS.

Separately, D. Boral Capital lowered their price objective on shares of Invivyd from $9.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, August 15th. One equities research analyst has rated the stock with a Strong Buy rating and three have issued a Buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $3.85.

Invivyd Trading Down 1.7%

IVVD opened at $0.5710 on Tuesday. The stock has a market capitalization of $68.60 million, a PE ratio of -0.62 and a beta of 0.51. Invivyd has a 1-year low of $0.3546 and a 1-year high of $2.74. The firm has a 50-day moving average price of $0.75 and a two-hundred day moving average price of $0.84.

Invivyd (NASDAQ:IVVD) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.08). The company had revenue of $11.79 million during the quarter, compared to analyst estimates of $23.16 million. Invivyd had a negative net margin of 238.33% and a negative return on equity of 177.89%.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in IVVD. Mithril II GP LP acquired a new position in shares of Invivyd during the 4th quarter worth about $4,981,000. AQR Capital Management LLC increased its stake in shares of Invivyd by 2,051.0% during the 1st quarter. AQR Capital Management LLC now owns 410,711 shares of the company’s stock worth $249,000 after purchasing an additional 391,617 shares during the last quarter. Two Sigma Advisers LP increased its stake in shares of Invivyd by 1,276.5% during the 4th quarter. Two Sigma Advisers LP now owns 304,200 shares of the company’s stock worth $135,000 after purchasing an additional 282,100 shares during the last quarter. Deutsche Bank AG raised its position in shares of Invivyd by 35.2% in the fourth quarter. Deutsche Bank AG now owns 874,406 shares of the company’s stock valued at $385,000 after purchasing an additional 227,463 shares during the period. Finally, Marshall Wace LLP bought a new position in shares of Invivyd in the second quarter valued at about $158,000. Institutional investors and hedge funds own 70.36% of the company’s stock.

Insider Buying and Selling at Invivyd

In other news, insider Jill Andersen sold 49,402 shares of the company’s stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $0.57, for a total value of $28,159.14. Following the completion of the transaction, the insider owned 84,446 shares in the company, valued at $48,134.22. This represents a 36.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 277,654 shares of company stock worth $167,215 over the last quarter. Company insiders own 25.40% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.